PAR-25-321-Full-Announcement.html

This is a Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI) under the Department of Health and Human Services for Exploratory/Developmental Bioengineering Research Grants (EBRG) with solicitation number PAR-25-321. The opportunity is for R21 clinical trial optional grants aimed at demonstrating feasibility and utility of new bioengineering capabilities or improvements in biomedical, pre-clinical, or clinical research and care delivery.

The funding opportunity is open to a wide range of applicants including higher education institutions, government entities, nonprofits, small businesses, and tribal organizations. It falls under multiple cancer-related grant programs (CFDA 93.393-93.396, 93.399) covering cancer biology, detection, diagnosis, treatment, prevention, and control research. The programs specifically focus on developing improved methods for cancer screening, early detection, diagnosis, treatment evaluation, risk identification, and prevention strategies to enhance quality of life for cancer survivors.